Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.

Delmedica has achieved some significant milestones over the last few months which will go a long way to help them commercialise their MucoAd technology.

The significant developments are listed below:

- Industrialisation of the bench scale process has been carried out with two industrial scale batches being produced in the facilities of Unifarm in Sofia, Bulgaria. The batches were both within the quality specs proving not only the scalability of the product but also its reproducibility. A paper is currently being prepared for submission to a major journal.

- An abstract entitled “Difference in Tear Clearance Times between Standard Fluorescein Solution and a Novel Muco-adhesive Fluorescein Solution” has been submitted for the AAAAI conference in Philadelphia. The conclusion was that a non-irritative muco-adhesive solution with increased muco-adhesiveness delayed tear clearance assessed by fluorescein compared to standard, diagnostic fluorescein solution. The muco-adhesive solution was better tolerated.

- An abstract entitled “The Effect of Delivering Fluorescein or Saccharine in a Novel Muco-adhesive Solution on Nasal Mucociliary Clearance” has been submitted for the AAAAI conference in Philadelphia. The conclusion was that methylcellulose solutions with increased muco-adhesiveness delayed nasal mucociliary clearance assessed by two separate measurements: time to taste saccharine (subjective) and fluorescein appearance in the pharynx (objective). The fluorescein muco-adhesive solution was better tolerated than standard fluorescein.

- The Bio-Availability study for Metacam in a MucoAd carrier has been initiated and is expected to be finished by December 2007. The results will be submitted for publication in top journals.

- The NDA (new drug application) dossier for Xylocaine has now been finished.

Delmedica can also report some progress with the exhaled breath temperature device and the hiring of two new people to strengthen the team:

- Initial results show that there appears to be a correlation with increased EBT and the onset of TB, further research is being carried out.

- Discussions are currently ongoing with Venture Corporation (a Singapore listed company) to miniaturise the device and add ergonomics and electronics. This improved device will be marketed to the scientific community to increase the awareness of EBT as a diagnostic tool.

- An article describing the EBT device and its operation has been published in the “Journal of Respiratory Medicine” in the October 2007 issue. The article is titled “Evaluation of a Simple, Potentially Individual Device for Exhaled Breath Temperature Measurement”. The following link will take you to the abstract http://dx.doi.org/10.1016/j.rmed.2007.06.005.

- The NDA (new drug application) dossier for Xylocaine has now been finished.